Trials / Unknown
UnknownNCT04191941
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Adoptive Immunotherapy for Hematological Malignancy With Novel CAR-T Cells.
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Timmune Biotech Inc. · Industry
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.
Detailed description
The Novel CAR-T contains either a scFv plus a PD-L1 blocker, or two scFvs, in a cytokine complex based outer memberane structure, this kind of structure enables the CAR-T cells to simultaneously target one or two targets on the tumor cell surface and enhance CAR-T cell persistence in tumor microenvironment，as well as stimulating innate T/NK cell activation and expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Novel CAR-T | A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2021-08-31
- Completion
- 2021-12-31
- First posted
- 2019-12-10
- Last updated
- 2019-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04191941. Inclusion in this directory is not an endorsement.